Table 1.
Summary of the design and structure of clinically tested bioresorbable scaffolds
| Scaffold | Strut material | Coating material | Eluted drug | Strut thickness (μm) | Resorption (month) | Current status |
|---|---|---|---|---|---|---|
| Igaki-Tamai | PLLA | None | None | 170 | 24–36 | CE mark for peripheral use |
| AMS-1 | Mg | None | None | 165 | <4 | Discontinued |
| DREAMS-1 | Mg | PLGA | Paclitaxel | 125 | 9 | Clinical trials |
| DREAMS-2 | Mg | PLLA | Sirolimus | 150 | 9 | Clinical trials |
| Absorb BVS 1.0 | PLLA | PDLLA | Everolimus | 156 | 18–24 | Discontinued |
| Absorb BVS 1.1 | PLLA | PDLLA | Everolimus | 156 | 24–48 | CE mark |
| Absorb BVS-New generation | PLLA | PDLLA | Everolimus | <100 | NA | NA |
| DeSolve | PLLA | None | Myolimus | 150 | 12–24 | CE mark |
| DeSolve 100 | PLLA | PLLA | Novolimus | 100 | 24 | CE mark |
| IDEAL biostent | Polymer salicylate | Salicylate | Sirolimus | 175 | >12 | Clinical trials |
| REVA | PTD-PC | None | None | 200 | 24 | Discontinued |
| ReZolve | PTD-PC | None | Sirolimus | 115–230 | 4–6 | Clinical trials |
| ReZolve2 | PTD-PC | None | Sirolimus | 100 | 48 | Clinical trials |
| Fantom | PTD-PC | - | Sirolimus | 125 | 36 | Clinical trials |
| Fortitude | semicrystalline polylactide | - | None | 150–200 | 3–6 | Clinical trials |
| Mirage BRMS | PLLA | - | Sirolimus | 125–150 | 14 | Clinical trials |
| MeRes | PLLA | PDLLA | Sirolimus | 100 | 24 | Clinical trials |
| Xinsorb | PLLA | PDLLA | Sirolimus | 160 | 24–36 | Clinical trial |
| ART 18AZ | PDLLA | None | None | 170 | 3–6 | Clinical trials |
Mg magnesium, PLLA poly-L-lactic acid, PDLLA poly-DL-lactic acid, BVS bioresorbable vascular scaffold
SA/AA salicylic acid/adipic acid, PTD-PC, poly-tyrosine-derived polycarbonate, CE Conformité
Européenne. NA not available